WINT [NASD]
Windtree Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.48 Insider Own2.80% Shs Outstand28.30M Perf Week1.55%
Market Cap12.29M Forward P/E- EPS next Y-0.52 Insider Trans18.75% Shs Float21.41M Perf Month-10.68%
Income-66.80M PEG- EPS next Q-0.14 Inst Own5.20% Short Float4.01% Perf Quarter-62.59%
Sales- P/S- EPS this Y-31.30% Inst Trans-10.46% Short Ratio1.10 Perf Half Y-69.96%
Book/sh1.23 P/B0.35 EPS next Y1.50% ROA-84.10% Target Price3.40 Perf Year-81.21%
Cash/sh0.54 P/C0.79 EPS next 5Y- ROE-145.60% 52W Range0.38 - 2.40 Perf YTD-73.43%
Dividend- P/FCF- EPS past 5Y60.50% ROI- 52W High-82.23% Beta0.31
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low12.80% ATR0.04
Employees33 Current Ratio3.50 Sales Q/Q- Oper. Margin- RSI (14)39.63 Volatility8.00% 8.91%
OptionableNo Debt/Eq0.43 EPS Q/Q43.30% Profit Margin- Rel Volume0.09 Prev Close0.42
ShortableYes LT Debt/Eq0.43 Earnings- Payout- Avg Volume778.90K Price0.43
Recom1.00 SMA20-2.71% SMA50-23.53% SMA200-65.85% Volume73,094 Change2.28%
Jun-26-20Initiated Ladenburg Thalmann Buy $12.25
Jun-29-22 08:00AM  
May-23-22 10:12AM  
May-16-22 07:00AM  
May-05-22 04:05PM  
Apr-20-22 04:05PM  
07:00AM  
Mar-31-22 04:05PM  
03:26PM  
07:05AM  
Mar-22-22 01:47PM  
07:30AM  
Mar-15-22 12:06PM  
07:00AM  
Mar-10-22 08:00AM  
Feb-01-22 02:36PM  
07:30AM  
Dec-15-21 08:00AM  
Nov-22-21 04:59PM  
08:00AM  
Nov-10-21 04:05PM  
Oct-26-21 10:33AM  
08:51AM  
Oct-25-21 07:30AM  
Oct-20-21 07:36AM  
Oct-14-21 07:30AM  
Oct-12-21 07:30AM  
Sep-30-21 02:25PM  
Sep-16-21 07:30AM  
Aug-05-21 04:01PM  
Aug-02-21 08:00AM  
Jul-08-21 11:20AM  
07:30AM  
Jul-07-21 07:30AM  
Jul-01-21 07:30AM  
Jun-23-21 09:35AM  
Jun-09-21 06:40AM  
May-13-21 07:30AM  
Apr-19-21 07:00AM  
Apr-09-21 02:16PM  
Mar-30-21 10:13AM  
Mar-29-21 05:10PM  
Mar-25-21 04:15PM  
Mar-23-21 08:30AM  
Mar-22-21 04:05PM  
07:00AM  
Mar-15-21 07:00AM  
Mar-08-21 07:00AM  
Feb-22-21 08:18AM  
Feb-16-21 07:00AM  
Feb-04-21 08:30AM  
Feb-01-21 04:30PM  
Jan-06-21 08:00AM  
Nov-24-20 06:15AM  
Nov-16-20 07:45AM  
Oct-01-20 07:30AM  
Sep-29-20 07:30AM  
Sep-08-20 08:00AM  
Aug-31-20 12:06PM  
Aug-13-20 07:36PM  
Jul-21-20 07:00AM  
Jul-20-20 07:00AM  
Jun-30-20 08:43AM  
Jun-24-20 08:00AM  
May-28-20 08:00AM  
May-22-20 04:05PM  
May-20-20 08:30AM  
May-14-20 08:00AM  
Apr-29-20 07:45AM  
Apr-28-20 04:05PM  
Apr-06-20 07:45AM  
Apr-02-20 07:30PM  
Mar-31-20 07:45AM  
Mar-24-20 07:45AM  
Dec-09-19 08:00AM  
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fraser CraigPresident and CEOJun 29Buy0.427,0002,908217,058Jun 30 06:59 AM
Fraser CraigPresident and CEOMar 16Buy0.982,0001,960210,058Mar 17 05:33 PM
Simonson StevenSVP, Chief Medical OfficerMar 15Buy1.005,0004,99983,602Mar 15 04:48 PM
Fraser CraigPresident and CEOMar 15Buy0.983,0002,940208,058Mar 15 04:45 PM
Center Laboratories, Inc.10% OwnerDec 30Buy1.601,239,0881,982,5411,239,088Jan 10 05:03 PM
Bioengine Capital Inc.10% OwnerDec 30Sale1.601,239,0881,982,5410Jan 10 05:03 PM
Fraser CraigPresident and CEONov 19Buy1.609301,48838,158Nov 22 08:35 AM
Fraser CraigPresident and CEONov 18Buy1.619301,49737,228Nov 18 04:25 PM
Fraser CraigPresident and CEOOct 22Buy1.903,0005,70036,298Oct 25 09:17 AM
Huang JamesDirectorOct 19Buy1.9050,00095,135291,281Oct 19 04:56 PM
Fraser CraigPresident and CEOOct 19Buy1.913,0005,73033,298Oct 19 04:51 PM